Edwards Lifesciences Sapien XT trial in Japan
This article was originally published in The Gray Sheet
Executive SummaryEdwards Lifesciences' Sapien XT valve is being studied in Japan's first transcatheter aortic heart valve clinical trial, the firm announces April 26. Three leading Japanese cardiovascular centers are participating in the PREVAIL JAPAN trial, which will evaluate Sapien XT in Japanese patients suffering from severe aortic stenosis. Edwards says a successful trial could lead to Japanese approval by as early as 2013. The NovaFlex transfemoral and Ascendra 2 transapical delivery systems will both be studied in the trial. Sapien XT launched on a controlled basis in Europe in March and a full ramp-up is planned for the second quarter (1"The Gray Sheet" April 26, 2010)
You may also be interested in...
India’s Sun Pharma has been denied leave to appeal against a US court decision rejecting the company’s bid for dismissal of a multi-district antitrust lawsuit.
Former Sandoz executive Hector Armando Kellum has admitted involvement in a US generic price-fixing conspiracy, the US Department of Justice has announced.